• Vaccine Name: Influenza Vaccine with rHA antigen and 1V270 adjuvant
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Type: Subunit vaccine
• Status: Licensed
• Host Species for Licensed Use: Mouse
• Host Species as Laboratory Animal Model: Mouse
• Preparation: rHA derived from A/Puerto Rico/8/1934 (PR/8) was chosen as the vaccine antigen in order to concentrate upon HA-specific immunity that is protective against a homologous challenge; the recombinant hemagglutinin (rHA) antigens derived from influenza viruses A/Puerto Rico/8/1934 (H1N1) (PR/8) and A/California/04/2009 (H1N1) (Cal/09) and the chimeric HAs (cHAs) (cH2/1PR/8 and cH6/1PR/8) were expressed from baculovirus in High Five cells in the laboratory as soluble trimers utilizing the T4 phage fibritin natural trimerization domain and a C-terminal 6× His tag for purification (Goff et al., 2015)
• Immunization Route: Intramuscular injection (i.m.)

Baboon Response

• Immune Response: 1V270 potently generates Th1 cellular immunity; the combination of 1Z105 and 1V270 with a recombinant HA induces rapid, long-lasting, and balanced Th1- and Th2-type immunity; 1V270 and the combination of 1V270 and 1Z105 promoted OVA-specific IFN-γ release by T cells restimulated ex vivo; 1V270, alone and in combination with 1Z105, induced both IgG1 and IgG2a in a more balanced Th1-Th2-type response; protective immunity to the 2009 pandemic H1N1 (pH1N1) virus -- 1Z105 and 1V270, alone and in combination, and AddaVax enhanced the IgG seroresponse (Goff et al., 2015)